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Influenza A virus (IAV) infections lead to severe inflammation in the airways. Patients with
chronic obstructive pulmonary disease (COPD) characteristically have exaggerated airway
inflammation and are more susceptible to infections with severe symptoms and increased
mortality. The mechanisms that control inflammation during IAV infection and the
mechanisms of immune dysregulation in COPD are unclear. We found that IAV infections
lead to increased inflammatory and antiviral responses in primary bronchial epithelial cells
(pBECs) from healthy nonsmoking and smoking subjects. In pBECs from COPD patients,
infections resulted in exaggerated inflammatory but deficient antiviral responses. A20 is an
important negative regulator of NF-kB–mediated inflammatory but not antiviral responses,
and A20 expression was reduced in COPD. IAV infection increased the expression of miR-
125a or -b, which directly reduced the expression of A20 and mitochondrial antiviral
signaling (MAVS), and caused exaggerated inflammation and impaired antiviral responses.
These events were replicated in vivo in a mouse model of experimental COPD. Thus, miR-
125a or -b and A20 may be targeted therapeutically to inhibit excessive inflammatory
responses and enhance antiviral immunity in IAV infections and in COPD.
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Introduction
Influenza A viruses (IAVs) are among the most important infectious human pathogens that cause enormous 
morbidity and mortality worldwide. This largely results from seasonal influenza, but an important feature of  
the biology of  IAVs is the frequent emergence of  novel pandemic strains/subtypes. Infections cause symp-
toms ranging from mild to severe viral pneumonia, with uncontrolled inflammation in the airways.
Bronchial epithelial cells (BECs) are the primary site of  IAV infection, and innate immune responses 
produced by these cells are important in the early protection against the viruses (1, 2). During infection, 
viral RNAs are recognized by TLR3 and retinoic acid-inducible gene-I (RIG-I). Upon binding of  TLR3 to 
viral RNAs, signalling pathways are initiated that activate receptor interacting protein 1 (RIP1) by ubiq-
uitination. Activated RIP1 indirectly phosphorylates IκBα, leading to the release of  active p65 and p50 
subunits of  NF-κB into the nucleus, where they induce the transcription of  inflammatory genes including 
cytokines such as IL-6, TNF-α, and IL-1β and chemokines such as CXC chemokine ligand-8 (CXCL-8/
IL-8) (3–5). These inflammatory cytokines recruit immune cells, in particular macrophages and neutro-
phils, to the site of  infection that phagocytose pathogens and apoptotic cells (6, 7). RIG-I interacts with 
mitochondrial antiviral-signaling protein (MAVS), which activates interferon regulatory factor 3 (IRF3) by 
phosphorylation. Activated IRF3 then translocates into the nucleus, where it initiates the production of  
type I and III IFNs (8, 9). These innate cytokines induce the transcription of  over 300 IFN-stimulated genes 
(ISGs), including the Mx1 protein that disrupts virus replication (10).
The control of  inflammation is critical to achieving optimal inflammatory responses that clear viruses 
without excessive damage to host tissues and airways. We have previously shown that A20, also known 
as TNF-α–inducing protein 3 (TNFAIP3), is a negative regulator of  NF-κB–mediated inflammation that 
Influenza A virus (IAV) infections lead to severe inflammation in the airways. Patients with chronic 
obstructive pulmonary disease (COPD) characteristically have exaggerated airway inflammation 
and are more susceptible to infections with severe symptoms and increased mortality. The 
mechanisms that control inflammation during IAV infection and the mechanisms of immune 
dysregulation in COPD are unclear. We found that IAV infections lead to increased inflammatory 
and antiviral responses in primary bronchial epithelial cells (pBECs) from healthy nonsmoking and 
smoking subjects. In pBECs from COPD patients, infections resulted in exaggerated inflammatory 
but deficient antiviral responses. A20 is an important negative regulator of NF-κB–mediated 
inflammatory but not antiviral responses, and A20 expression was reduced in COPD. IAV infection 
increased the expression of miR-125a or -b, which directly reduced the expression of A20 and 
mitochondrial antiviral signaling (MAVS), and caused exaggerated inflammation and impaired 
antiviral responses. These events were replicated in vivo in a mouse model of experimental COPD. 
Thus, miR-125a or -b and A20 may be targeted therapeutically to inhibit excessive inflammatory 
responses and enhance antiviral immunity in IAV infections and in COPD.
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functions by targeting RIP1 for degradation, and therefore suppresses NF-κB activation (11–14). Micro-
RNAs (miRNAs) are another important class of  immune signaling regulators that silence gene expression 
by degradation (15). miR-125a and -b have recently been shown to directly inhibit A20, leading to increased 
NF-κB activation (16). It is currently unknown if  A20 or miR-125a or -b regulates type I and III IFNs 
during IAV infections.
Chronic obstructive pulmonary disease (COPD) is the third leading cause of  illness and death globally 
and is characterized by progressive airway inflammation, emphysema, and reduced lung function (17). 
The most important risk factor for COPD in Western societies is cigarette smoking (18). COPD patients 
have increased susceptibility to IAV infections that cause acute exacerbations and result in more severe 
symptoms, disease progression, and increased mortality (19–21). Current therapeutics remain limited to 
vaccination and antiviral drugs. These have major issues with the constant need for developing new vac-
cines. COPD patients respond poorly to vaccination, as IAVs have become drug resistant and all therapeu-
tics have questions surrounding availability and efficacy in future pandmics (22, 23). There is therefore an 
urgent need to develop novel therapeutics for influenza, especially for those most susceptible to infection.
Despite inflammatory signalling pathways being well characterized, the mechanisms underlying the 
exaggerated inflammatory responses to IAV, including in COPD, are unclear. It is known that increased 
NF-κB activation is elevated in biopsies from COPD patients (24). We have previously shown that human 
influenza H3N2 infection induced heightened inflammatory responses (25), and high pathogenic avian 
H5N1is known to induce severe cytokine storms in the lung (9, 26). We also showed that primary BECs 
(pBECs) from COPD subjects and our established in vivo model of  experimental COPD have increased 
inflammatory and impaired antiviral responses to IAV infections, leading to more severe infection (27–29). 
Furthermore, miRNAs are known to be altered in COPD (30, 31). However, the molecular mechanisms 
underpinning the heightened inflammatory response in IAV infections and defective immune responses 
in COPD remain unclear. In this study, we investigated the mechanisms involved using our established 
experimental systems (27, 32–34). We found that COPD pBECs and mice with experimental COPD 
infected with IAV have higher levels of  inflammatory cytokines but reduced antiviral responses (30, 35). 
We uncovered that NF-κB–mediated inflammation in IAV infection and in COPD was also exaggerated 
and resulted from decreased levels of  A20 protein, which in turn was caused by elevated levels of  miR-
125a or -b. Treatment with specific antagomirs against miR-125a or -b reduced NF-κB activation but also 
increased type I and III IFN production and suppressed infection. We then found that miR-125a and -b 
directly target MAVS 3′-UTR, thereby suppressing the induction of  type I and III IFNs. This study there-
fore discovers an miR-125–mediated pathway that reduces A20 and MAVS, promotes excessive inflamma-
tion, and increases susceptibility to IAV infection in COPD. It also identifies potential therapeutic options 
that reduce IAV-mediated inflammation and reverse immune signaling abnormalities in COPD.
Some of  the data has been previously reported in abstract form (36).
Results
IAV infection induces increased inflammatory but reduced antiviral responses ex vivo in human COPD pBECs. pBECs 
from healthy nonsmoking control subjects, COPD patients (ex-smoker), or smoking (smoker) controls were 
infected with IAV H3N2 or H1N1 (MOI 5). Virus replication was measured 24 hours after infection. Virus 
titers increased at 24 hours (Figure 1A) and were 2-fold greater in COPD pBECs compared with controls. 
Infection resulted in the production of  the proinflammatory cytokines/chemokines IL-6, CXCL-8, TNF-α, 
and IL-1β and antiviral cytokines type I (IFN-β) and type III interferons (IFN-λ1) (Figure 1B). In COPD, 
the induction levels of  cytokines were substantially higher (2.5–10 fold) compared with healthy control and 
smoker pBECs (Figure 1B). In contrast, the induction of  IFN-β and IFN-λ1 proteins were reduced in COPD.
We then measured the levels of  activity of  NF-κB by assessing the levels of  phosphorylated p65 (phos-
pho-p65) at Ser536 (35, 37, 38). Infection significantly increased the activation of  phospho-p65 in both healthy 
and smoker pBECs at 6 hours, which was further increased at 24 hours (Figure 1C and Supplemental Figure 
1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.90443DS1). 
In COPD pBECs, the protein levels of  phospho-p65 was elevated at baseline (media controls) at 6 hours and 
significantly increased with infection at 24 hours compared with healthy and smoker controls.
IAV infection also induces increased inflammatory but reduced antiviral responses in vivo in experimental 
COPD. We then demonstrated these events also occur in vivo. BALB/c mice were exposed to either 
normal air (Air) or cigarette smoke (Smk) for 8 weeks. The Smk group develops hallmark features of  
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COPD as previously described (27, 28, 32–35, 39). Mice were then infected with IAV A/PR/8/34, and 
viral titers, airway inflammation (histopathological score), and inflammatory and antiviral cytokines 
were determined at 7 days postinfection (dpi) (Figure 2A). Infection in Air-exposed controls leads to 
virus replication (Figure 2B) that was accompanied by significant airway inflammation (histopatholog-
ical score, Supplemental Figure 1B). Infection in Smk-exposed mice resulted in a significantly higher 
Figure 1. IAV infection is more severe and results in exaggerated inflammatory but impaired antiviral responses in 
pBECs from patients with COPD. pBECs from healthy controls, COPD patients, and healthy smokers were infected with 
human IAV H3N2 or H1N1, and (A) virus replication was measured at 24 hours. (B) Proinflammatory cytokines/chemo-
kines IL-6, CXCL-8, TNF-α, and IL-1β and antiviral cytokines IFN-β and IFN-λ1 were measured in culture supernatants at 
24 hours. (C) Phospho-p65 was assessed at 6 hours and 24 hours, and densitometry results (from Supplemental Figure 
1A, representative immunoblot) were calculated as phospho-p65/GAPDH ratios and expressed as fold change from 
healthy media control. Data are mean ± SEM, n = 15 (healthy controls and COPD patients) or 5 (healthy smokers). *P ≤ 
0.05 versus respective uninfected media control, +P ≤ 0.05 versus infected or uninfected healthy controls. Statistical 
differences were determined with one-way ANOVA followed by Bonferroni post-test.
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virus titer (4-fold) and airway histopathological score (3-fold) compared with Air-exposed mice. In sup-
port of  these data, the levels of  the proinflammatory cytokines/chemokines IL-6, KC (mouse equivalent 
of  CXCL-8), TNF-α, and IL-1β were also increased by infection in Air-exposed groups and to a greater 
extent in Smk-exposed groups (Figure 2C). Antiviral cytokines were increased in infected Air-exposed 
controls but were either not induced (IFN-β) or were induced to a much reduced level (IFN-λ3) in infect-
ed Smk-exposed groups (Figure 2D). The exaggerated release of  proinflammatory cytokines was associ-
ated with significantly increased levels of  phospho-p65 protein in infected Smk-exposed compared with 
Air-exposed controls (Figure 2E and Supplemental Figure 1C). In all experiments, ultraviolet-inactivated 
virus did not have any effects compared with media controls (data not shown).
Taken together, these human ex vivo and experimental in vivo data demonstrate that IAV infections result 
in increased airway inflammation and proinflammatory and antiviral responses. However, COPD is associ-
ated with exaggerated inflammation and reduced antiviral responses, leading to increased virus replication.
A20 is an important negative regulatory of  NF-κB–mediated inflammatory but not antiviral responses, and 
its expression is reduced in human COPD and experimental COPD. We have previously shown that A20 is an 
important negative regulator of  NF-κB activation (11–14), but its roles during IAV infection and whether it 
also regulates the induction of  type I and III IFNs is unclear. We hypothesized that A20 protein expression 
would be downregulated and would contribute to the increased activation of  NF-κB in response to IAV 
infection in COPD. IAV infection led to a significant induction of  A20 protein at 6 hours and 24 hours in 
healthy and smoker controls, but this increase was impaired in COPD pBECs (Figure 3A and Supplemen-
tal Figure 2A). Similarly in Smk-exposed mice, A20 protein expression was reduced in airway epithelial 
cells compared with Air-exposed controls (Supplemental Figure 2B).
We then investigated if  A20 was important in NF-κB–mediated inflammatory responses and if  exag-
gerated p65 activation was the direct result of  reduced A20 protein levels during infection in COPD pBECs. 
Figure 2. IAV infection is more severe and results in 
exaggerated inflammatory and impaired antiviral 
responses in experimental COPD. (A) BALB/c mice 
were exposed to cigarette smoke (Smk) or normal air 
(Air) for 8 weeks, infected with IAV H1N1 (A/PR/8/34, 
8 pfu) or media (Sham) on the last day of smoke 
exposure, and sacrificed 7 days postinfection (dpi). (B) 
Virus titers were measured in bronchoalveolar lavage 
fluid. (C) IL-6, KC, TNF-α, and IL-1β and (D) IFN-β 
and IFN-λ3 were assessed in lung homogenates. 
(E) Phospho-p65 protein was determined in lung 
homogenates. Densitometry results (from Supple-
mental Figure 1D, representative immunoblot) were 
calculated as phospho-p65 or IFN-β/β-actin ratios 
and expressed as fold change from Air sham control. 
Data are mean ± SEM, n = 6–8 per group. *P ≤ 0.05 
versus Sham control, +P ≤ 0.05 versus Air control. 
Statistical differences were determined with one-way 
ANOVA followed by Bonferroni post-test.
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We inhibited A20 expression using A20-specific siRNA 24 hours before infection and measured the activa-
tion of  p65 and the production of  proinflammatory cytokines/chemokines 24 hours after infection. Inhi-
bition of  A20 expression (Figure 3B and Supplemental Figure 2C) resulted in significant increases in the 
protein levels of  phospho-p65 (Figure 3C and Supplemental Figure 2C) and proinflammatory cytokines/
chemokines IL-6, CXCL-8, TNF-α, and IL-1β (Figure 3D) compared with untreated controls, whether 
pBECs were infected or not. Conversely, ectopic expression (ecto-expression) using a pcDNA-A20 expres-
sion vector reduced the phosphorylation of  p65 (Supplemental Figure 2D). Nevertheless, inhibition or 
ecto-expression of  A20 did not affect IFN-β and IFN-λ1 induction (Figure 3E and Supplemental Figure 
2D). siRNA negative control or control vector did not affect the induction of  A20 or phospho-p65 protein 
(Supplemental Figure 2, E and F).
Collectively, these data indicate that A20 is an important negative regulator of  NF-κB but is dispens-
able in the induction of  type I and III IFNs. A20 protein expression is dysregulated in COPD.
Elevated miR-125a and -b levels decrease A20 levels, increase inflammation and impair antiviral responses in 
COPD pBEC and experimental COPD. miR-125a and -b have recently been shown to directly target and inhib-
it A20 expression (16), but their roles during IAV infection and in COPD are unknown. Thus, we measured 
the levels of  miR-125a and -b induced by IAV infection. H3N2 and H1N1 infections resulted in significant 
increases in the levels of  these miRNAs at 24 hours in pBECs from all groups (Figure 4A). However, their 
levels were substantially greater at baseline and during infection (2- to 4-fold) in COPD pBECs compared 
with healthy controls. We then confirmed the direct link between increased miR-125a and -b levels and 
Figure 3. A20 expression is reduced and negatively regulates inflammatory but not antiviral responses in pBECs from patients with COPD. (A) pBECs were 
infected with human IAV H3N2 or H1N1, and the protein levels of A20 were determined at 6 hours and 24 hours. Densitometry results (from Supplemental 
Figure 2A, representative immunoblot) were calculated as A20 or phospho-p65/GAPDH ratios and expressed as fold change from healthy media control. 
Data are mean ± SEM, n = 15 per group. *P ≤ 0.05 versus respective uninfected media control, +P ≤ 0.05 versus healthy control. A20 expression was inhibited 
with a specific siRNA, pBECs were infected with IAVs, and protein levels of (B) A20; (C) phospho-p65; (D) cytokines/chemokines IL-6, CXCL-8, TNF-α, and 
IL-1β; and antiviral (E) IFN-β and IFN-λ1 were measured 24 hours later. Densitometric ratios (from Supplemental Figure 2C, representative immunoblot) were 
expressed as fold change from untreated media control. Data are mean ± SEM, n = 3 per group. *P ≤ 0.05 versus untreated, uninfected media control, +P ≤ 
0.05 versus untreated infected or uninfected control. Statistical differences were determined with one-way ANOVA followed by Bonferroni post-test.
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Figure 4. IAV infection increases the levels of miR-125 and -b that suppress the production of A20, increase inflammatory responses, and reduce 
antiviral responses in human COPD pBECs and experimental COPD. pBECs were infected with human IAV H3N2 or H1N1, and (A) miR-125a and -b 
levels were assessed at 24 hours. Data are mean ± SEM, n = 15 per group. *P ≤ 0.05 versus uninfected media control, +P ≤ 0.05 versus healthy or smoker 
control. (B) pBECs were treated with miR-125a or -b antagomir and were infected, and the levels of A20, phospho-p65, IFN-β, and IFN-λ1 were assessed. 
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reduced A20 protein induction using specific antagomirs and mimetics. pBECs were pretreated with either 
miR-125a or -b specific antagomirs or mimetics for 24 hours before infection, and A20, phospho-p65, 
inflammatory, and antiviral cytokines were assessed 24 hours after infection. Antagomir treatment inhib-
ited miR-125a or -b expression (Supplemental Figure 3A), and this resulted in significant increases in A20 
protein production, reduced phosphorylation of  p65, subsequent induction of  proinflammatory cytokines/
chemokines, and enhanced antiviral IFN-β and -λ1 responses (Figure 4B and Supplemental Figure 3, B–E) 
compared with untreated controls. Conversely, miR-125a or -b mimetics decreased A20 protein induction, 
increased phospho-p65protein levels, and reduced IFN-β responses (Supplemental Figure 3F). Treatment 
with scrambled miRNA or mimetic controls did not affect A20, phospho-p65, or IFN-β production (Sup-
plemental Figure 3, G and H).
We then assessed whether similar events occurred in vivo. IAV infection significantly increased the 
levels of  miR-125a and -b in both groups, with the levels in Smk group significantly higher compared with 
Air-exposed controls (Figure 4C). We then inhibited miR-125a or -b before and during infection (Figure 
4D). We also extended the ex vivo data by inhibiting both miR-125a and -b together. Treatment with miR-
125a or -b antagomir, alone or in combination, reduced histopathological scores (Figure 4E and Supple-
mental Figure 4A) and improved lung function (reduced lung volume determined during a pressure-volume 
loop maneuver) in Air- and Smk-exposed groups compared with infected scrambled antagomir-treated 
controls (Supplemental Figure 4B). Inhibition of  miR-125a, -b, or -a and -b, also increased A20 protein 
expression in the airway epithelium and decreased the levels of  phospho-p65 compared with the controls 
(Figure 4F and Supplemental Figure 4, C and D). Importantly, while we could only detect reductions in 
TNF-α and KC with combined treatment (Supplemental Figure 4E), antagomir treatment, either alone or 
in combination, also significantly increased IFN-β and IFN-λ3 protein induction (Figure 4F and Supple-
mental Figure 4D).
Collectively, these data show that miR-125a and -b are directly involved in the regulation of  both 
inflammatory cytokines — through the control of  A20 — and antiviral cytokine production through an 
unknown target.
miR-125a and -b target MAVS. To determine the mechanism of  miR-125a– and -b–mediated regulation 
of  antiviral IFN-β/λ, we performed miRNA prediction analysis using TargetScan (www.targetscan.org). 
miR-125a and -b have a putative binding site in the 3′-UTR of  human and mouse MAVS (Figure 5, A 
and B). To examine these putative interactions, we first assessed the protein levels of  MAVS in pBECs. 
MAVS protein levels were significantly increased 24 hours after IAV infection in healthy control and smok-
er pBECs, but notably not in COPD pBECs Figure 5C and Supplemental Figure 5A). Similarly, infection 
in Smk-exposed mice was also associated with significantly impaired production of  MAVS compared with 
infected Air-exposed controls at 7 dpi (Figure 5D and Supplemental Figure 5B).
To confirm the potential interaction of  miR-125a or -b and MAVS, we cloned the putative binding 
region of  miR-125a and -b in WT (MAVS-WT) or mutant (MAVS-MT) MAVS 3′-UTR into a luciferase 
reporter construct. The construct was cotransfected into HEK293 cells along with miR-125a or -b mimetics, 
or scrambled controls, and then luciferase activity was assessed. Cotransfection of  miR-125a or miR-125b 
mimetics with MAVS-WT resulted in a significant decrease in luciferase activity compared with scrambled 
controls (Figure 5E). There was no reduction in activity with cotransfection with MAVS-MT. We then deter-
mined if  MAVS gene is present with the miR-125a or -b mimetics in the silencing complex. To do this, we 
immunoprecipitated Argonaute 2 (Ago2), a core component of  RNA-induced silencing complex (RISC) 
that binds to the miRNAs and their target mRNA, with a specific antibody and detected the presence of  both 
Densitometry results (Supplemental Figure 3B, representative immunoblot) were calculated as A20 or phospho-p65/GAPDH ratios and expressed as fold 
change from untreated, uninfected control. Data are mean ± SEM, n = 3 per group. *P ≤ 0.05 versus untreated, uninfected media control; +P ≤ 0.05 versus 
untreated infected or uninfected group. (C) BALB/c mice were exposed to cigarette smoke (Smk) or normal air (Air) for 8 weeks, inoculated with IAV H1N1 
(A/PR/8/34, 8 pfu) or media (Sham) on the last day of smoke exposure, and sacrificed 7 days postinfection (dpi). The levels of miR-125a and -b were 
measured. Data are mean ± SEM, n = 6–8 per group. *P ≤ 0.05 versus Sham group, +P ≤ 0.05 versus Air-infected or uninfected group. (D) In other groups, 
on the last day of smoke exposure, mice were treated with miR-125a or -b antagomir alone or in combination and infected with IAV, and (E) airway his-
tological scores were assessed. Data are mean ± SEM, n = 6–8 per group. *P ≤ 0.05 versus infected and scrambled treated Air controls, +P ≤ 0.05 versus 
infected and scramble-treated Smk group. (F) The protein levels of A20, phospho-p65, and IFN-β in lung homogenates were also measured. Densitom-
etry results (Supplemental Figure 4D) were calculated as A20 or phospho-p65/β-actin ratios and expressed as fold change from untreated, uninfected 
control. Data are mean ± SEM, n = 6–8 per group. *P ≤ 0.05 versus infected scrambled-treated Air group, +P ≤ 0.05 versus infected scrambled Smk group. 
Statistical differences were determined with one-way ANOVA followed by Bonferroni post-test.
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Figure 5. miR-125a and -b target a functional binding site of the 3′-UTR of the mRNA of MAVS to suppress its expression. (A) Representation of 
MAVS gene structure and location of miR-125a and -b binding site. (B) The binding site on 3′-UTR of MAVS is 100% conserved between human and 
mouse MAVS. (C) pBECs were infected with H3N2 or H1N1, and MAVS protein was detected at 6 hours (left) and 24 hours (right). Densitometry results 
(Supplemental Figure 5A, representative immunoblot) were calculated as MAVS/GAPDH ratios and expressed as fold change from untreated, unin-
fected controls. Data are mean ± SEM, n = 15 per group. *P ≤ 0.05 versus uninfected healthy or smoker controls, +P ≤ 0.05 versus infected or uninfect-
ed healthy controls. (D) BALB/c mice were exposed to cigarette smoke (Smk) or normal air (Air) for 8 weeks, inoculated with IAV H1N1 (A/PR/8/34, 
8 pfu) or media (Sham) on the last day of smoke exposure, and sacrificed 7 days postinoculation (dpi). The levels of MAVS protein were measured in 
lung homogenates. Densitometry results (Supplemental Figure 5B, representative immunoblot) were calculated as MAVS/β-actin ratios in mouse 
and expressed as fold change from untreated, uninfected controls. Data are mean ± SEM, n = 6 per group. *P ≤ 0.05 versus Sham-treated controls, 
+P ≤ 0.05 versus infected Air controls. (E) The miR-125a and -b binding site on 3′-UTR was cloned into a pMIR luciferase reporter construct and trans-
fected into HEK293 cells with miR-125a or -b mimetics. The luciferase reporter assay was performed to determine binding. Data are mean ± SEM, n 
= 3 per group.*P ≤ 0.05 versus miRNA scrambled controls. (F) Ago2 was immunoprecipitated from miR-125a or -b mimetic-transfected HEK293, and 
(G) A20 and MAVS mRNA was detected by qPCR in Ago2-immunoprecipitate. Data are mean ± SEM, n = 3 per group. *P ≤ 0.05 versus IgG control IP. 
Statistical differences were determined with one-way ANOVA followed by Bonferroni post-test.
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A20 and MAVS by qPCR, which could not be detected with immunoprecipitation with IgG control (Figure 
5, F and G). This confirmed that miR-125a and -b directly bind to the endogenous 3′-UTR of  MAVS.
miR-125a and -b targeting of  MAVS regulates antiviral responses in COPD pBEC and experimental COPD. We 
then investigated whether inhibition of  miR-125 has a functional outcome. We showed that miR-125a and 
-b antagomir treatment led to significant increases in MAVS (Figure 6A and Supplemental Figure 6, A 
and B), IFN-β, and IFN-λ1 protein induction (Figure 4B and Supplemental Figure 3C) and reduced viral 
replication in both healthy and control pBECs (Figure 6B). In contrast, mimetics suppressed the induction 
of  antiviral cytokines and increased virus titers (Supplemental Figure 3F). Similarly in Smk-exposed mice, 
inhibition of  miR-125a, -b, or -a and -b resulted in increased induction of  MAVS (Figure 6C and Supple-
mental Figure 6C), IFN-β, and IFN-λ3 (Figure 4F and Supplemental Figure 4, D and E) and inhibited virus 
replication (Figure 6D).
Collectively, these data demonstrate that miR-125a and -b negatively regulate MAVS expression, sup-
press the induction of  IFN-β/λ, and may potentially be targeted therapeutically in the prevention and/or 
treatment of  IAVs and COPD.
Discussion
Here, we discovered that IAV infections induce airway inflammation and antiviral responses; however, 
in COPD, pBECs and experimental COPD inflammatory responses and activation of  NF-κB are exag-
gerated, but antiviral responses are impaired. We show that A20 is a negative regulator of  NF-κB–medi-
ated induction of  inflammatory but not antiviral cytokines and that A20 protein levels were impaired in 
Figure 6. miR-125a and -b suppress the induction of MAVS and promote virus replication in human COPD pBECs and experimental COPD. (A) miR-125a 
and -b antagomir or mimetics were added to pBECs before infection with human IAV H3N2 or H1N1, and mitochondrial antiviral signaling (MAVS) protein 
were assessed 24 hours after infection. Densitometry results (Supplemental Figure 6A, representative immunoblot) were calculated as MAVS/GAPDH 
ratios and expressed as fold change from untreated, uninfected controls. Data are mean ± SEM, n = 3. *P ≤ 0.05 versus untreated, uninfected media 
controls; +P ≤ 0.05 versus untreated, infected or uninfected controls. (B) Virus replication was also measured. Data are mean ± SEM, n = 3. *P ≤ 0.05 versus 
untreated, infected controls. (C) BALB/c mice were exposed to cigarette smoke (Smk) or normal air (Air) for 8 weeks, treated with mir125a and/or -b antag-
omir, infected with IAV H1N1 (A/PR/8/34, 8 pfu) or media (Sham) on the last day of smoke exposure, and sacrificed 7 days postinoculation (dpi). MAVS 
protein was measured. Densitometry results (Supplemental Figure 6C, representative immunoblot) were calculated as MAVS/β-actin ratios and expressed 
as fold change from untreated, uninfected controls. Data are mean ± SEM, n = 6. *P ≤ 0.05 versus infected, scramble treated Air or Smk controls. (D) Virus 
replication was assessed. Data are mean ± SEM, n = 6. *P ≤ 0.05 versus infected, scramble-treated controls. Statistical differences were determined with 
one-way ANOVA followed by Bonferroni post-test.
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COPD. The impaired induction of  A20 and antivi-
ral responses in COPD were attributed to increased 
expression of  miR-125a and -b. Elevated levels of  
these miRNAs suppressed A20 expression, leading 
to heightened NF-κB activity and inflammation and 
reduced antiviral responses. Inhibition with miR-
125a and -b antagomirs increased A20 levels and 
reduced NF-κB activity, and also promoted IFN 
production. We then demonstrated that miR-125a 
and -b modulated IFN induction by targeting MAVS 
translation. MAVS protein levels were reduced in 
COPD but could be increased with specific miR-
125a and -b antagomir treatment that also induced IFN production. Thus, IAV infection induces the 
expression of  miR-125a or -b that suppresses A20 and MAVS, in turn promoting NF-κB–induced 
inflammation and attenuating antiviral IFN production, respectively, increasing viral replication. All 
these events are exaggerated in COPD (Figure 7).
IAV is a major infectious pathogen that poses serious health concerns worldwide. Infections, par-
ticularly with highly pathogenic influenza viruses, cause severe airway inflammation and a cytokine 
storm with high morbidity and mortality. COPD is a major global health problem that is underpinned by 
exaggerated inflammatory responses in the airways (40). IAV infections frequently result in acute exacer-
bations of  COPD, leading to accelerated declines in lung function (41, 42) and increased mortality (20). 
The mechanisms of  exaggerated inflammation and severe outcomes in COPD are poorly understood, 
and there are no effective therapies for these events.
Here, we show that IAV-mediated inflammatory response are dampened with ectopic expression 
of  A20 that reduces NF-κB activity and inflammatory responses, without affecting type I and III IFN 
responses. A20 is a deubiquitinating enzyme that degrades RIP1, inhibits NF-κB activation (13), and 
has been shown to suppress the induction of  IFN-β (43). We found that A20 modulated NF-κB activity 
and inflammation, but it did not affect type I and III IFNs production.
Consistent with our previous findings (27), IAV infections in COPD pBECs and experimental 
COPD led to heightened inflammation and production of  inflammatory cytokines but impaired antivi-
ral responses (IFN-β and IFN-λ), which were associated with greater viral replication. Increased inflam-
mation, inflammatory cytokines, and activation of  NF-κB are well known in COPD (24, 44). Here, 
we show that these are the result of  reduced induction of  A20, leading to uncontrolled activation of  
NF-κB and subsequent induction of  inflammatory cytokines. A20 is a pleiotropic protein involved in 
various ubiquitin-dependent pathways, including NF-κB (16) and MAPK pathway (45), and has also 
been shown to negatively regulate type I IFN inductions (43, 46, 47). Surprisingly, inhibition or ectopic 
expression of  A20 did not affect IFN-β production. The precise roles of  A20 during viral infections, 
therefore, require further investigation. We could not rule out that other factors may also contribute to 
the regulation of  A20 expression and of  NF-κB activity, including other unidentified miRNAs, which 
may also be dysregulated in COPD.
Forced expression of  A20 may be a novel therapeutic option that reduces IAV-mediated inflammation 
and cytokine storm, particularly from high pathogenic IAVs, such as H5N1, or in COPD where airway 
inflammation is already persistently heightened.
The lack of  the induction of  A20 protein during IAV infection in COPD was attributed to increased 
levels of  miR-125a and -b. These miRNAs downregulate A20 expression by directly binding to its 3′-UTR, 
Figure 7. Roles of miR-125a and -b in the regulation of 
inflammatory and antiviral responses in IAV infection. 
Increased levels of miR-125a and -b, for example in COPD, 
reduce the protein expression of A20 that results in uncon-
trolled NF-κB activation, leading to exaggerated induction 
of proinflammatory cytokines. miR-125a and -b also target 
and reduce MAVS and antiviral type I and III IFN production. 
Inhibition of miR-125a and -b enhances MAVS and antiviral 
responses, and it suppresses viral infection.
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leading to constitutive activation of  NF-κB (16). We found that heightened levels of  miR-125a or -b resulted 
in increased activation of  NF-κB in COPD. Inhibition of  miR-125a or -b in both healthy and COPD pBECs 
and in experimental COPD increased A20 protein levels and reduced NF-κB activation during IAV infection.
We also found that miR-125a and -b modulated the induction of  type I and III antiviral IFNs. This 
occurred by the direct targeting of  MAVS 3′-UTR, therefore downregulating the subsequent induction of  
IFN-β and IFN-λ. MAVS is an important adaptor protein on mitochondria that facilitates the production 
of  IFNs (8); however, there was an impaired induction of  MAVS by IAV infections in COPD pBECs and 
in experimental COPD. Inhibition of  miR-125a and/or -b increased the levels of  MAVS and antiviral 
IFNs, which led to reduced virus replication both in vivo and in vitro. Interestingly, antagomirs against 
miR-125a and/or -b in experimental COPD partially reduced the release of  inflammatory cytokines and 
substantially suppressed virus replication. This may indicate that miR-125a and -b may preferentially 
target MAVS over A20 during IAV infection in COPD, although such binding preferences of  miRNAs 
have not been widely investigated. Furthermore, as MAVS is transcriptionally driven by IFN-sensitive 
response element (ISRE) as part of  the ISGs (48), and miR-125a or -b have been reported to be induced by 
NF-κB (49), it is possible that reduced MAVS partly attributed to impaired IFNs in COPD; with enhanced 
expression of  miR-125a or -b (NF-κB–inducible), this then leads to a continuous cycle of  exaggerated 
inflammation and impaired antiviral immunity in COPD.
Although miR-125a or -b appear to be NF-κB inducible, the exact molecular mechanisms of  enhanced 
miR-125a or -b expression in COPD require further investigation. In colorectal cancer tissues, the levels of  
miR-125a have been shown to be reduced, which is associated with hypermethylation at the CpG island with-
in the promoter region of  miR-125a (50). Similarly, in breast cancer cell lines, reduced miR-125a has also been 
shown to be associated with trimethylation at H3K9 and H3K27 at the promoter region of  miR-125a (51). It 
is therefore possible that the methylation status of  miR-125a or -b promoter site is altered in COPD, leading 
to increased expression of  miR-125a or -b. Nevertheless, our data also demonstrate that specific inhibition of  
miR-125a or -b may be a novel therapeutic option against IAV infections and for those most vulnerable.
Cigarette smoke is the major risk factor for COPD. Acute exposure results in oxidative stress and NF-κB 
activation (52–54). However, the effects we have observed in COPD appear to be independent of  acute expo-
sure to cigarette smoking, as the pBECs obtained from subjects with COPD were all abstinent from smoking 
for at least 10 years. It is likely that chronic exposure progressively leads to persistent induction of  miR-125a 
and -b and NF-κB activation (55, 56), which then reduces the induction of  A20 and MAVS in COPD.
Collectively, our results demonstrate that A20 regulates NF-κB activation and, subsequently, the pro-
duction of  inflammatory cytokines, but not antiviral IFNs. COPD pBECs and mice with experimental 
COPD responded to IAV infection with an exaggerated inflammatory but impaired antiviral responses. 
Increased levels of  miR-125a and -b by IAV and in COPD suppressed protein inductions of  A20 and 
Table 1. Subject characteristics
Healthy COPD Smoker P value
n 15 15 5 NA
Sex (male/female ratio) 1.14 1.2 1.5 P = 0.6
Mean age (SD) 62 (9.9) 68 (4.1) 64.33 (12.82) P = 0.06
Mean FEV1 (SD)A 105% (13.5) 40% (7.75) 97.66% (12.66) P < 0.001
FEV1/FVC ratio (SD)A 886 (14.50) 40.20 (13.50) 77.80 (12.28) P < 0.001
Cigarette (packs/year; SD) 0 53.70 (15.90) 30 (17.32) P < 0.001
Years abstinent (SD) 0 13.0 (4.64) 0 NA








AFEV1 and FEV1/FVC ratios are % predicted values. FEV1 is the forced expiratory volume in 1s expressed as a percentage of the predicated value. FVC is 
forced vital capacity. The statistical analysis used was ANOVA for multiple groups. NA, not applicable.
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MAVS, leading to heightened airway inflammation and reduced IFN production. Inhibition of  miR-125a 
and -b reduced the induction of  inflammatory cytokines and enhanced antiviral responses to IAV infection 
in both healthy and COPD states. This study therefore identifies a potential therapeutic target for IAV 
infection in general and in COPD.
Methods
Ex vivo. COPD patients (10) and healthy nonsmoking (10) and smoking (5) controls were recruited, and 
their characteristics are shown in Table 1. Subject recruitment, viruses, cell culture and viral infection, A20 
plasmid, siRNA, miR-125a and -b antagomir/mimetic treatment, cloning and mutagenesis of  miR-125a 
and -b binding sites in MAVS 3′-UTR, reporter assays, immunoblotting, cytometric bead array, immuno-
precipitation, miRNA extraction and analysis, and statistical tests were performed as previously described 
and/or as in Supplemental Methods (27, 31, 57, 58).
In vivo. Experimental COPD and influenza infection were induced; miR-125a and -b were inhib-
ited using specific antagomirs; and histopathology, IHC, immunoblotting, and cytometric bead array 
and data analyses were performed as previously described and/or as in Supplemental Methods (33, 
35, 39, 59–67).
Statistics. When data were normally distributed, they were expressed as mean ± SEM. Data were ana-
lyzed using nonparametric equivalents and summarized using the median and interquartile range (IQR) 
when non-normally distributed. Multiple comparisons were first analyzed by the Kruskal Wallis test and 
then by individual testing, if  significant. P < 0.05 was considered significant. 
Study Approval. All procedures were approved by The University of  Newcastle Human and Animal 
Ethics Committees.
Author contributions
ACYH conceived and designed the study. ACYH and KN performed all in vitro experiments. KD, TJH, 
and PMN performed all in vivo experiments. ACYH, KD, MRS, TJH, PMN, KN, NZ, STG, KJB, PSF, 
PMH, and PAW participated in the completion of  the manuscript.
Acknowledgments
This study is funded by National Health and Medical Research Council of  Australia (grant no. 1045762) 
and University of  Newcastle (grant no. 1300661). The authors thank Kristy Wheeldon and Nathalie Kiaos 
for technical assistance with in vivo protocols.
Address correspondence to: Alan Hsu or Phil Hansbro, Priority Research Centre for Healthy Lungs, 
Hunter Medical Research Institute, Lot 1 Kookaburra Circuit, New Lambton Heights, Newcastle, 
NSW 2305, Australia. Phone: 61.2.4042.0109; E-mail: Alan.Hsu@newcastle.edu.au (A. Hsu); Philip.
Hansbro@newcastle.edu.au (P. Hansbro).
 1. Hallstrand TS, Hackett TL, Altemeier WA, Matute-Bello G, Hansbro PM, Knight DA. Airway epithelial regulation of  pulmo-
nary immune homeostasis and inflammation. Clin Immunol. 2014;151(1):1–15.
 2. Hsu AC, See HV, Hansbro PM, Wark PA. Innate immunity to influenza in chronic airways diseases. Respirology. 
2012;17(8):1166–1175.
 3. Chaouat A, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest. 2009;136(3):678–687.
 4. Meylan E, et al. RIP1 is an essential mediator of  Toll-like receptor 3-induced NF-kappa B activation. Nat Immunol. 
2004;5(5):503–507.
 5. Monks BG, Martell BA, Buras JA, Fenton MJ. An upstream protein interacts with a distinct protein that binds to the cap site of  
the human interleukin 1 beta gene. Mol Immunol. 1994;31(2):139–151.
 6. Tate MD, Ioannidis LJ, Croker B, Brown LE, Brooks AG, Reading PC. The role of  neutrophils during mild and severe influen-
za virus infections of  mice. PLoS ONE. 2011;6(3):e17618.
 7. Hashimoto Y, Moki T, Takizawa T, Shiratsuchi A, Nakanishi Y. Evidence for phagocytosis of  influenza virus-infected, apoptot-
ic cells by neutrophils and macrophages in mice. J Immunol. 2007;178(4):2448–2457.
 8. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of  MAVS, a mitochondrial antiviral signaling protein that 
activates NF-kappaB and IRF 3. Cell. 2005;122(5):669–682.
 9. Hsu AC, et al. Critical role of  constitutive type I interferon response in bronchial epithelial cell to influenza infection. PLoS 
ONE. 2012;7(3):e32947.
 10. Verhelst J, Parthoens E, Schepens B, Fiers W, Saelens X. Interferon-inducible protein Mx1 inhibits influenza virus by interfering 
with functional viral ribonucleoprotein complex assembly. J Virol. 2012;86(24):13445–13455.
1 3insight.jci.org   https://doi.org/10.1172/jci.insight.90443
R E S E A R C H  A R T I C L E
 11. Heyninck K, et al. The zinc finger protein A20 inhibits TNF-induced NF-kappaB-dependent gene expression by interfering with 
an RIP- or TRAF2-mediated transactivation signal and directly binds to a novel NF-kappaB-inhibiting protein ABIN. J Cell Biol. 
1999;145(7):1471–1482.
 12. Heyninck K, Beyaert R. The cytokine-inducible zinc finger protein A20 inhibits IL-1-induced NF-kappaB activation at the level 
of  TRAF6. FEBS Lett. 1999;442(2-3):147–150.
 13. Grey ST, Arvelo MB, Hasenkamp W, Bach FH, Ferran C. A20 inhibits cytokine-induced apoptosis and nuclear factor kap-
paB-dependent gene activation in islets. J Exp Med. 1999;190(8):1135–1146.
 14. Ferran C, et al. A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated 
apoptosis. Blood. 1998;91(7):2249–2258.
 15. Foster PS, et al. The emerging role of  microRNAs in regulating immune and inflammatory responses in the lung. Immunol Rev. 
2013;253(1):198–215.
 16. Kim SW, Ramasamy K, Bouamar H, Lin AP, Jiang D, Aguiar RC. MicroRNAs miR-125a and miR-125b constitutively activate 
the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA. 
2012;109(20):7865–7870.
 17. World Health Organization. Chronic Obtructive Pulmonary Disease (COPD) Fact Sheet. http://www.who.int/mediacentre/
factsheets/fs315/en/. Published November 2016. Accessed February 20, 2017.
 18. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of  disease and risk factors, 2001: sys-
tematic analysis of  population health data. Lancet. 2006;367(9524):1747–1757.
 19. Hurst JR, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
 20. Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations 
and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931.
 21. Seemungal T, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(9):1618–1623.
 22. Nath KD, et al. Clinical factors associated with the humoral immune response to influenza vaccination in chronic obstructive 
pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2014;9:51–56.
 23. Hurt AC, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med. 2011;365(26):2541–2542.
 24. Di Stefano A, et al. Increased expression of  nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. 
Eur Respir J. 2002;20(3):556–563.
 25. Hsu AC, Barr I, Hansbro PM, Wark PA. Human influenza is more effective than avian influenza at antiviral suppression in air-
way cells. Am J Respir Cell Mol Biol. 2011;44(6):906–913.
 26. Chan MC, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and 
bronchial epithelial cells. Respir Res. 2005;6:135.
 27. Hsu AC, et al. Targeting PI3K-p110α Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease. Am J 
Respir Crit Care Med. 2015;191(9):1012–1023.
 28. Beckett EL, et al. A new short-term mouse model of  chronic obstructive pulmonary disease identifies a role for mast cell trypt-
ase in pathogenesis. J Allergy Clin Immunol. 2013;131(3):752–762.
 29. Hsu AC, et al. Impaired Antiviral Stress Granule and IFN-β Enhanceosome Formation Enhances Susceptibility to Influenza 
Infection in Chronic Obstructive Pulmonary Disease Epithelium. Am J Respir Cell Mol Biol. 2016;55(1):117–127.
 30. Tay HL, et al. Antagonism of  miR-328 increases the antimicrobial function of  macrophages and neutrophils and rapid clear-
ance of  non-typeable Haemophilus influenzae (NTHi) from infected lung. PLoS Pathog. 2015;11(4):e1004549.
 31. Conickx G, et al. MicroRNA Profiling Reveals a Role for MicroRNA-218-5p in the Pathogenesis of  Chronic Obstructive Pul-
monary Disease. Am J Respir Crit Care Med. 2017;195(1):43–56.
 32. Fricker M, Deane A, Hansbro PM. Animal models of  chronic obstructive pulmonary disease. Expert Opin Drug Discov. 
2014;9(6):629–645.
 33. Franklin BS, et al. The adaptor ASC has extracellular and ‘prionoid’ activities that propagate inflammation. Nat Immunol. 
2014;15(8):727–737.
 34. Hansbro PM, et al. Importance of  mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental 
chronic obstructive pulmonary disease and colitis. J Biol Chem. 2014;289(26):18214–18227.
 35. Haw TJ, et al. A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary 
disease. Mucosal Immunol. 2016;9(4):859–872.
 36. Mehra NK. A brief  history of  the Federation of  Immunological Societies of  Asia-Oceania (FIMSA). Ann N Y Acad Sci. 
2013;1283:v–x.
 37. Hussain S, et al. Inflammasome activation in airway epithelial cells after multi-walled carbon nanotube exposure mediates a 
profibrotic response in lung fibroblasts. Part Fibre Toxicol. 2014;11:28.
 38. Higham A, Lea S, Ray D, Singh D. Corticosteroid effects on COPD alveolar macrophages: dependency on cell culture method-
ology. J Immunol Methods. 2014;405:144–153.
 39. Liu G, et al. Fibulin-1 regulates the pathogenesis of  tissue remodeling in respiratory diseases. JCI Insight. 2016;1(9):e86380.
 40. Asher MI, et al. Worldwide time trends in the prevalence of  symptoms of  asthma, allergic rhinoconjunctivitis, and eczema in 
childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743.
 41. Kanner RE, Anthonisen NR, Connett JE, Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) 
decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health 
study. Am J Respir Crit Care Med. 2001;164(3):358–364.
 42. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of  exacerbation on quality of  life in 
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5 Pt 1):1418–1422.
 43. Wang YY, Li L, Han KJ, Zhai Z, Shu HB. A20 is a potent inhibitor of  TLR3- and Sendai virus-induced activation of  NF-kap-
paB and ISRE and IFN-beta promoter. FEBS Lett. 2004;576(1-2):86–90.
 44. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest. 2008;118(11):3546–3556.
 45. Jung SM, et al. Smad6 inhibits non-canonical TGF-β1 signalling by recruiting the deubiquitinase A20 to TRAF6. Nat Commun. 
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.90443
R E S E A R C H  A R T I C L E
2013;4:2562.
 46. Saitoh T, et al. A20 is a negative regulator of  IFN regulatory factor 3 signaling. J Immunol. 2005;174(3):1507–1512.
 47. Maelfait J, et al. A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog. 
2012;8(3):e1002570.
 48. Rusinova I, et al. Interferome v2.0: an updated database of  annotated interferon-regulated genes. Nucleic Acids Res. 
2013;41(Database issue):D1040–D1046.
 49. Lee HM, Kim TS, Jo EK. MiR-146 and miR-125 in the regulation of  innate immunity and inflammation. BMB Rep. 
2016;49(6):311–318.
 50. Chen H, Xu Z. Hypermethylation-Associated Silencing of  miR-125a and miR-125b: A Potential Marker in Colorectal Cancer. 
Dis Markers. 2015;2015:345080.
 51. Cisneros-Soberanis F, Andonegui MA, Herrera LA. miR-125b-1 is repressed by histone modifications in breast cancer cell lines. 
Springerplus. 2016;5(1):959.
 52. Kirkham PA, Barnes PJ. Oxidative stress in COPD. Chest. 2013;144(1):266–273.
 53. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflam-
mation. Int J Chron Obstruct Pulmon Dis. 2011;6:413–421.
 54. Kratsovnik E, Bromberg Y, Sperling O, Zoref-Shani E. Oxidative stress activates transcription factor NF-kB-mediated protective 
signaling in primary rat neuronal cultures. J Mol Neurosci. 2005;26(1):27–32.
 55. Tan G, Niu J, Shi Y, Ouyang H, Wu ZH. NF-κB-dependent microRNA-125b up-regulation promotes cell survival by targeting 
p38α upon ultraviolet radiation. J Biol Chem. 2012;287(39):33036–33047.
 56. Werner SL, et al. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators Ikappa-
Balpha and A20. Genes Dev. 2008;22(15):2093–2101.
 57. Gómez FP, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic 
obstructive pulmonary disease. Curr Opin Pulm Med. 2002;8(2):81–86.
 58. . Workshop summary guidelines: investigative use of  bronchoscopy, lavage, bronchial biopsies in asthma other airway diseases. 
J Allergy Clin Immunol. 1991;88(5):808–814.
 59. Horvat JC, et al. Chlamydial respiratory infection during allergen sensitization drives neutrophilic allergic airways disease. 
J Immunol. 2010;184(8):4159–4169.
 60. Thorburn AN, Foster PS, Gibson PG, Hansbro PM. Components of  Streptococcus pneumoniae suppress allergic airways dis-
ease and NKT cells by inducing regulatory T cells. J Immunol. 2012;188(9):4611–4620.
 61. Essilfie AT, et al. Macrolide therapy suppresses key features of  experimental steroid-sensitive and steroid-insensitive asthma. 
Thorax. 2015;70(5):458–467.
 62. Plank MW, et al. MicroRNA Expression Is Altered in an Ovalbumin-Induced Asthma Model and Targeting miR-155 with 
Antagomirs Reveals Cellular Specificity. PLoS ONE. 2015;10(12):e0144810.
 63. Preston JA, et al. Inhibition of  allergic airways disease by immunomodulatory therapy with whole killed Streptococcus pneu-
moniae. Vaccine. 2007;25(48):8154–8162.
 64. Asquith KL, et al. Interleukin-13 promotes susceptibility to chlamydial infection of  the respiratory and genital tracts. PLoS Pathog. 
2011;7(5):e1001339.
 65. Starkey MR, et al. Constitutive production of  IL-13 promotes early-life Chlamydia respiratory infection and allergic airway dis-
ease. Mucosal Immunol. 2013;6(3):569–579.
 66. Starkey MR, et al. Tumor necrosis factor-related apoptosis-inducing ligand translates neonatal respiratory infection into chronic 
lung disease. Mucosal Immunol. 2014;7(3):478–488.
 67. Kim RY, et al. MicroRNA-21 drives severe, steroid-insensitive experimental asthma by amplifying phosphoinositide 
3-kinase-mediated suppression of  histone deacetylase 2. J Allergy Clin Immunol. 2017;139(2):519–532.
